共 230 条
[1]
Di Angelantonio E(2015)Association of cardiometabolic multimorbidity with mortality JAMA 314 52-60
[2]
Kaptoge S(2011)Long-term effects of intensive glucose lowering on cardiovascular outcomes N Engl J Med 364 818-828
[3]
Wormser D(2008)Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes N Engl J Med 358 2560-2572
[4]
Willeit P(2015)Heart failure in diabetes: effects of anti-hyperglycaemic drug therapy Lancet 385 2107-2117
[5]
Butterworth AS(2007)Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes N Engl J Med 356 2457-2471
[6]
Bansal N(2007)Thiazolidinediones and heart failure: a teleo-analysis Diabetes Care 30 2148-2153
[7]
Gerstein HC(2014)Cardiovascular outcome trials of glucose-lowering drugs or strategies in type 2 diabetes Lancet 383 2008-2017
[8]
Miller ME(2008)Assessing the cardiovascular safety of diabetes therapies N Engl J Med 359 1092-1095
[9]
Genuth S(2016)Incretin-based therapy for diabetes what a cardiologist needs to know J Am Coll Cardiol 67 1488-1496
[10]
Ismail-Beigi F(2012)Lowering of postprandial lipids in individuals with type 2 diabetes treated with alogliptin and/or pioglitazone: a randomised double-blind placebo-controlled study Diabetologia 55 915-925